Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,049 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Time is myelin: early cortical myelin repair prevents atrophy and clinical progression in multiple sclerosis.
Lazzarotto A, Hamzaoui M, Tonietto M, Dubessy AL, Khalil M, Pirpamer L, Ropele S, Enzinger C, Battaglini M, Stromillo ML, De Stefano N, Filippi M, Rocca MA, Gallo P, Gasperini C, Stankoff B, Bodini B; MAGNIMS Study Group. Lazzarotto A, et al. Among authors: gallo p. Brain. 2024 Apr 4;147(4):1331-1343. doi: 10.1093/brain/awae024. Brain. 2024. PMID: 38267729 Free PMC article.
Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial.
Kappos L, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH, Montalbán X, Barkhof F, Radü EW, Metzig C, Bauer L, Lanius V, Sandbrink R, Pohl C; BENEFIT Study Group. Kappos L, et al. Lancet Neurol. 2009 Nov;8(11):987-97. doi: 10.1016/S1474-4422(09)70237-6. Epub 2009 Sep 10. Lancet Neurol. 2009. PMID: 19748319 Free article. Clinical Trial.
Natalizumab in pediatric multiple sclerosis: results of a cohort of 55 cases.
Ghezzi A, Pozzilli C, Grimaldi LM, Moiola L, Brescia-Morra V, Lugaresi A, Lus G, Rinaldi F, Rocca MA, Trojano M, Bianchi A, Comi G, Filippi M; Italian MS Study Group. Ghezzi A, et al. Mult Scler. 2013 Jul;19(8):1106-12. doi: 10.1177/1352458512471878. Epub 2013 Feb 11. Mult Scler. 2013. PMID: 23401129
Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO study.
O'Connor P, Comi G, Freedman MS, Miller AE, Kappos L, Bouchard JP, Lebrun-Frenay C, Mares J, Benamor M, Thangavelu K, Liang J, Truffinet P, Lawson VJ, Wolinsky JS; Teriflunomide Multiple Sclerosis Oral (TEMSO) Trial Group and the MRI-AC in Houston, Texas. O'Connor P, et al. Neurology. 2016 Mar 8;86(10):920-30. doi: 10.1212/WNL.0000000000002441. Epub 2016 Feb 10. Neurology. 2016. PMID: 26865517 Free PMC article. Clinical Trial.
A comparison of natalizumab and ocrelizumab on disease progression in multiple sclerosis.
Iaffaldano P, Lucisano G, Guerra T, Paolicelli D, Portaccio E, Inglese M, Foschi M, Patti F, Granella F, Romano S, Cavalla P, De Luca G, Gallo P, Bellantonio P, Gallo A, Montepietra S, Di Sapio A, Vianello M, Quatrale R, Spitaleri D, Clerici R, Torri Clerici V, Cocco E, Brescia Morra V, Marfia GA, Boccia VD, Filippi M, Amato MP, Trojano M; Italian MS Register. Iaffaldano P, et al. Among authors: gallo p, gallo a. Ann Clin Transl Neurol. 2024 Aug;11(8):2008-2015. doi: 10.1002/acn3.52118. Epub 2024 Jul 5. Ann Clin Transl Neurol. 2024. PMID: 38970214 Free PMC article.
Effects of fingolimod on focal and diffuse damage in patients with relapsing-remitting multiple sclerosis - The "EVOLUTION" study.
Filippi M, Pagani E, Turrini R, Bartezaghi M, Brescia Morra V, Borriello G, Torri Clerici V, Mirabella M, Pasquali L, Patti F, Totaro R, Gallo P, Rocca MA; Evolution Study Group. Filippi M, et al. Among authors: gallo p. J Neurol. 2024 Sep;271(9):6181-6196. doi: 10.1007/s00415-024-12590-z. Epub 2024 Jul 29. J Neurol. 2024. PMID: 39073436
The contribution of paramagnetic rim and cortical lesions to physical and cognitive disability at multiple sclerosis clinical onset: evaluating the power of MRI and OCT biomarkers.
Miscioscia A, Mainero C, Treaba CA, Silvestri E, Scialpi G, Berardi A, Causin F, Anglani MG, Rinaldi F, Perini P, Puthenparampil M, Bertoldo A, Gallo P. Miscioscia A, et al. Among authors: gallo p. J Neurol. 2024 Oct;271(10):6702-6714. doi: 10.1007/s00415-024-12622-8. Epub 2024 Aug 19. J Neurol. 2024. PMID: 39155316
Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis.
Radue EW, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Rudick RA, Lublin FD, Weinstock-Guttman B, Wynn DR, Fisher E, Papadopoulou A, Lynn F, Panzara MA, Sandrock AW; SENTINEL Investigators. Radue EW, et al. J Neurol Sci. 2010 May 15;292(1-2):28-35. doi: 10.1016/j.jns.2010.02.012. Epub 2010 Mar 16. J Neurol Sci. 2010. PMID: 20236661 Clinical Trial.
Interferon β-1b-neutralizing antibodies 5 years after clinically isolated syndrome.
Hartung HP, Freedman MS, Polman CH, Edan G, Kappos L, Miller DH, Montalbán X, Barkhof F, Petkau J, White R, Sahajpal V, Knappertz V, Beckmann K, Lanius V, Sandbrink R, Pohl C; BENEFIT Study Group. Hartung HP, et al. Neurology. 2011 Aug 30;77(9):835-43. doi: 10.1212/WNL.0b013e31822c90d7. Epub 2011 Aug 17. Neurology. 2011. PMID: 21849647 Clinical Trial.
1,049 results